Valeant's looming M&A hiatus deals blow to investment banks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cowen Raises Price Target on AT&T (T) After Updating Model to Reflect Company Changes
October 27, 2015 10:24 AM EDTCowen reiterated an Outperform rating on AT&T (NYSE: T), and raised the price target to $41.00 (from $40.00), after updating model to reflect the new way in which the company breaks out revenue.
Analyst Colby Synesael commented, "We are updating our... More
Endo Int'l (ENDP), BioDelivery Sciences (BDSI) Announce FDA Approval of BELBUCA as Chronic Pain Treatment
October 26, 2015 6:26 AM EDTEndo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management, is... More
UBS Reiterates Buy on AT&T (T) Following 3Q Earnings
October 23, 2015 10:19 AM EDTUBS reiterated a Buy rating and $42.00 price target on AT&T (NYSE: T), following the company's 3Q earnings results. AT&T reported 3Q EPS of $0.74, equating to 14% yoy growth. 4Q seasonality should not be as bad as in past years, suggesting... More
